血液肿瘤患者中枢神经系统感染2024指南更新
该指南由德国血液与肿瘤医学会感染病工作组更新,基于系统文献综述与共识流程,针对血液或肿瘤疾病(含细胞治疗)成人患者中枢神经系统感染的诊断与治疗给出循证推荐,强调及时诊断与抗感染治疗以降低死亡率。
要点
- 中枢神经系统感染可见于高达15%的血液或肿瘤患者,病毒或真菌最常见。
- 延迟治疗增加死亡率,需及时启动诊断与抗感染治疗。
- 推荐强度与证据等级采用ESCMID标准,经多学科专家共识制定。
核心结论
- 循证推荐对改善高发病率与死亡率风险患者结局至关重要。
研究设计与样本
- 指南更新基于系统文献综述与逐步共识流程,涉及内科、血液、肿瘤、感染、神经、微生物和放射专家。
主要发现
- 中枢神经系统感染发生于高达15%的血液或肿瘤患者,尤其高危人群。
- 最常见病原体为病毒或真菌。
- 及时启动适当诊断与抗感染治疗至关重要,延迟治疗增加死亡率。
关键数值与推荐
- 推荐强度与证据等级遵循ESCMID标准。
- 最终推荐于2024年9月由德国血液与肿瘤医学会感染病工作组大会批准。
临床怎么用
- 对血液或肿瘤成人患者应警惕中枢神经系统感染,及时诊断与治疗以改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infections of the central nervous system (CNS) occur in up to 15 % of patients with hematological or oncological diseases (HOD), particularly in high-risk populations. The most common causative agents are viruses or fungi. Prompt initiation of adequate diagnostic procedures and anti-infective treatment is crucial, as treatment delays increase mortality. METHODS: We present an update of our previous guideline published in 2016 on the management of CNS infections in patients with HOD. The grading of recommendation strength and level of evidence followed the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) standards, based on a systematic literature review and a stepwise consensus process involving experts in internal medicine, hematology, oncology, infectious diseases, neurology, microbiology, and radiology. This process included several web-based meetings by the guideline panel, whereas the final recommendations were approved by the assembly of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology in September 2024. FINDINGS AND INTERPRETATION: Evidence-based recommendations on the diagnosis and treatment of CNS infections in adult patients with HOD are essential in daily clinical practice to improve outcomes for patients at high risk of morbidity and mortality.
引用
- Akdas R, Schalk E, Stemler J, et al. CNS infections in patients with hematological or oncological diseases (including cellular therapies) - 2024 update of the guideline of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Eur J Cancer. 2025. PMID: 41344068. doi:10.1016/j.ejca.2025.116103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。